Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers [3]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 211-212

  Güzey, Cüneyt ^a,b   Spigset, Olav ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MIANSERIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; CASE REPORT; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MALE; PHARMACOGENETICS; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS;

EID: 33646689555     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203225.79364.85     Document Type: Letter

References (10)

1. Charlier C, Pinto E, Ansseau M, et al. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol Clin Exp. 2000;15:453-459.
2. Norman C, Hörn M, Hummel B, et al. Paroxetine in major depression: correlating plasma concentration and clinical response. Pharmacopsychiatry. 2004;37:123-126.
3. Reis M, Åberg-Wistedt A, Ågren H, et al. Serum disposition of sertraline, N-desmethyl-sertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol Clin Exp. 2004;19:283-291.
4. Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51:278-287.
5. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004;60:553-557.
6. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit. 2003;25:738-742.
7. Sachse C, Brockmöller J, Bause S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
8. Güzey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry. 2000;61:600-601.
9. Dahl M-L, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995;274:516-520.
10. Bathum L, Johansson I, Ingelman-Sundberg M, et al. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics. 1998;8:119-123.